1. Pink Sheet
  2. >>Biosimilars & Generics

Biosimilar Antitrust Pressure On J&J Grows As Walgreen, Kroger Sue Over Remicade Contracts

 
• By Brenda Sandburg

Pharmacy chains object to J&J agreements with insurers that block coverage of Pfizer and Merck biosimilars except in 'rarest of circumstances'; seek overcharge damages for Remicade purchases.

court house

Walgreen Co. and The Kroger Co. are throwing their weight behind efforts to get a district court to halt Johnson & Johnson's exclusionary contracts that deter the purchase of biosimilars to J&J's Remicade (infliximab).

The two pharmacy chains filed suit against J&J and its subsidiary Janssen Biotech Inc. in the Eastern District of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Biosimilars & Generics

US Supreme Court Wants Solicitor General Input On Hikma Skinny Label Case

 
• By Dean Rudge

The US Supreme Court is seeking the administration's view following the Federal Circuit decided to reopen Amarin’s case against the ‘skinny-label’ generic Vascepa (icosapent ethyl).

Repurposed Drugs: EU Pharma Reform Offers Boost, But Payers ‘Must Recognize Health Gains’

 
• By Eliza Slawther

Incentives for repurposed drugs proposed as part of the EU pharma reform package are a “great step forward,” but more recognition is needed from payers and regulators to leverage the benefits of these medicines, experts say.

Canada Joins Global Push To Drop Costly Clinical Trials For Biosimilars

 
• By Neena Brizmohun

Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.